Trial
NCT01033019
To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Sporadic Superficial and Nodular Skin Basal Cell Carcinomas
Intervention
LDE225 0.75%
Why stopped
The data from participants with sBCCs showed insufficient efficacy with current formulation and treatment conditions.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-10-30